Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
30 hedge funds and large institutions have $4.04M invested in Vyant Bio, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.
232% more capital inflows, than outflows
Capital inflows: $1.41M | Capital outflows: $426K
0.9% more ownership
Funds ownership: 11.31% → 12.21% (+0.9%)
9% less funds holding
Funds holding: 33 → 30 (-3)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perkins Capital Management
Wayzata,
Minnesota
|
+$579K |
| 2 |
Anson Funds Management
Dallas,
Texas
|
+$555K |
| 3 |
Renaissance Technologies
New York
|
+$154K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
+$86.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$19.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$185K |
| 2 |
Eagle Global Advisors
Houston,
Texas
|
-$98K |
| 3 |
Beck Mack & Oliver
New York
|
-$36K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$30K |
VYNT Hedge Fund Activity: Q3 2016 in Review
30 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2016, worth a combined $4.04M — up 11% from $3.63M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VYNT and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Perkins Capital Management, adding an estimated $579K. The largest seller was Sabby Management, cutting an estimated $185K.
- 30 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2016, down from 33 in Q2 2016.
- Funds reported $4.04M of Vyant Bio, Inc. Common Stock stock for Q3 2016, up 11% quarter-over-quarter.
- 4 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2016 and 7 closed out, a net change of -3 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2016 was Perkins Capital Management, an estimated $579K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q3 2016 was Sabby Management, an estimated $185K sold.
Based on aggregated 13F filings for Q3 2016.